Ionis to host investor and analyst day event
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
- Ionis Innovation Day: Discovering, Developing and Delivering Transformational Medicines
- Presentations by key members of Ionis leadership and notable KOLs
- Henry N. Ginsberg, M.D., Irving professor of medicine, Vagelo College of Physicians and Surgeons, Columbia University; and
Raffi Tachdjian , M.D., MPH, FAAAAI, FACAAI, associate clinical professor of medicine and pediatrics, UCLA School of Medicine, and chief, division of allergy & immunology, Providence St. John Medical Center.
Please click here to register for the event. Webcast participants may submit questions via email at [email protected]. Questions must be received by
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-host-investor-and-analyst-day-event-301923994.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Ionis Pharmaceuticals (IONS) at Market Perform
- LogicSource Named to Inc. 5000 for Fifth Consecutive Year
- Food Safety Tech Launches FSTR to Bring Independent Benchmark Intelligence to the Food Industry
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share